Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults |
| |
Institution: | 1. Division of Allergic Diseases, Department of Medicine, USA;2. Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, USA;3. Allergy, Asthma & Immunology of the Rockies, PC., Glenwood Springs, CO, USA;4. Allergy & Immunology Program, National Institutes of Health, USA;5. Mayo Clinic, Rochester, MN, USA;6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA;7. Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH, USA |
| |
Abstract: | Antibody responses to pneumococcal polysaccharide vaccination are frequently used as a diagnostic tool for humoral immunodeficiencies, part of the larger collection of inborn errors of immunity. Currently, arbitrary criteria, such as a serotype specific titer of >/= 1.3 µg/mL is most often used as a cut-off for interpretation of pneumococcal antibody responses. The magnitude of the antibody response to each of the 23 serotypes in Pneumovax®, and serotype-specific cut-offs in healthy pneumococcal vaccine-naïve adults has not been previously characterized. IgG antibody concentrations were measured prospectively for 23 pneumococcal serotypes pre and 4–6 weeks post-Pneumovax® vaccination in 100 healthy adults, using a multiplex bead-based assay. Antibodies to 19 of 23 serotypes were informative for distinguishing subjects who responded to vaccination, and the serotype threshold was determined to be 9 of 19 serotypes, which characterized an antibody response to pneumococcal vaccination. While this study may facilitate classification of IgG serotype-specific antibody responses post-pneumococcal vaccination in adult patients undergoing diagnostic immunological evaluation for antibody immunodeficiencies or other relevant contexts, additional studies in healthy children and S. pneumoniae protein-conjugate-vaccinated healthy adults will need to be undertaken in the future. |
| |
Keywords: | Pneumococcal Serotype Pneumococcal polysaccharide vaccine Pneumovax® Pneumococcal conjugate vaccine Prevnar® Antibody response Humoral immunodeficiency Primary immunodeficiency Multiplex bead analysis PID"} {"#name":"keyword" "$":{"id":"k0060"} "$$":[{"#name":"text" "_":"primary immunodeficiencies PCV"} {"#name":"keyword" "$":{"id":"k0070"} "$$":[{"#name":"text" "_":"pneumococcal conjugate vaccine PPV"} {"#name":"keyword" "$":{"id":"k0080"} "$$":[{"#name":"text" "_":"pneumococcal polysaccharide vaccine IEI"} {"#name":"keyword" "$":{"id":"k0090"} "$$":[{"#name":"text" "_":"inborn errors of immunity |
本文献已被 ScienceDirect 等数据库收录! |
|